HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 09 & 10, September & October 2022 – Toxins and Medicines – Two Sides of the Same Coin       » Utilising Metal Nanoparticles as Plant Growth Regulators to Improve Crop Yield       » Remedy or Poison? How Microplastics Influence Copper Ion Toxicity in Aquatic Plants       » Synthesising Schiff Base Antimicrobial Copper Complexes With Unprecedented Speed       » Enhancing the Understanding of Past Infections With Machine Learning       » Mini, Cellular Bioweapons: Understanding the Structure and Mechanism of Stinging in Sea Anemone Nematocysts       » Converting Dead Spiders Into Gripping Tools
NEWS CRUNCH
BioSingapore Launches White Paper on the Future of BioSciences in Singapore
'The Next Lap - Biosciences in Singapore 2025'

SINGAPORE - The next 10 years of Singapore's biosciences industry is the focus of a new white paper that captures the views and predictions of the nation's biosciences industry leaders.

"The Next Lap - Biosciences in Singapore 2025" was produced in conjunction with Clearstate, an Economist Intelligence Unit business. It summarizes the development of Singapore's biosciences cluster to date and compares it with successful bioscience clusters in Israel, Taiwan and South Korea. The white paper provides insights on research and development and commercialisation opportunities, and highlights the talent needed to help Singapore sustain and entrench its position as the "Biopolis of Asia".

Simranjit Singh, Executive Council BioSingapore, said that over the past 15 years, Singapore has succeeded in building a reputation as a regional powerhouse in biosciences, but challenges such as limited resources and rising costs persist. He said there is a need for Singapore to increase its focus on key areas of research where it has a distinctive advantage.

Singh said: "The next phase of development presents new challenges & opportunities for Singapore as healthcare markets undergo transformational shifts on a global scale. As we look ahead to 2025, the bioscience sector should consider how best to create success stories that inspire more biosciences companies to establish & grow in Singapore."

Commercialisation remains at an early stage with big gaps in venture funding and management experience in bringing healthcare products to the market, he said. There are also opportunities untapped in emerging markets in Asia that could be a robust growth engine as demand for healthcare services in these markets is predicated to soar, Singh said.

About BioSingapore

BioSingapore, started by the Singapore Economic Development Board in 2004, is a leading life sciences association serving Singapore and the ASEAN region. Our vision is to enable a successful and vibrant life sciences community by connecting the industry to solutions.

Source: Quintiles
FORTHCOMING ISSUE  
What Has Covid Ever Done for Us?
NEWS CRUNCH  
news 2022 PDA Aseptic Processing of Biopharmaceuticals Conference
news Thailand LAB INTERNATIONAL, Bio Asia Pacific, and FutureCHEM INTERNATIONAL are ready to offer the Science and Technology Industry complete solutions this September!
news Better together: registration opens for Vitafoods Asia 2022 co-located with Fi Asia in October
news 2022 PDA Pharmaceutical Manufacturing & Quality Conference
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy